Search Results for 'Pfs Fulvestrant'

Emanuele Zucca, MD Oncology Institute of Southern Switzerland (IOSI)

• ellena-manuel
• 0 Slides

Swiss Group for Clinical Cancer Research (SAKK). ...

Raising the Bar in the Management of Advanced/Metastatic NSCLC

• debby-jeon
• 0 Slides

Dr Tan . Jiunn. Liang. Clinical Specialist (Resp...

Indolent Non-Hodgkin L

• danika-pritchard
• 0 Slides

ymphoma. Sobia Ozair. March 8, 2017. MD Anderson ...

A1 Using a Positive Family Support Screener to Inform Tiered Supports

• natalia-silvester
• 0 Slides

Strand:. Applied Evaluation. Recommended Experie...

PARP and Other DNA Damage Repair Inhibitors in Solid Tumors: An Update

• ellena-manuel
• 0 Slides

Program Overview . Discussion Outline. DNA Repair...

Pharmacist Focus on BTK Inhibitors Moderator Shilpa Paul, PharmD, BCOP

• ellena-manuel
• 25 Slides

Pharmacist Focus on BTK Inhibitors Moderator Shil...

The Impending D eath of Cancer: A Herculean Task Emerging Therapies 2016

• phoebe-click
• 33 Slides

The Impending D eath of Cancer: A Herculean Task...

Overall Survival Benefit of

• tatyana-admore
• 123 Slides

Obinutuzumab. Over Rituximab when Combined with ...

NEw developments IN gynecological Oncology

• cheryl-pisano
• 211 Slides

highlights from the. EUROPEAN . society . of med...

Ovarian Cancer Incidence/Mortality

• kittie-lecroy
• 41 Slides

Improvement in 5 Year Survival:. Race. 1975. 1989...

Ovarian cancer with update from ASCO 2013

• karlyn-bohler
• 39 Slides

Siew. . wei. . wong. Oncology registrar. Epidem...

Romidepsin in Association with CHOP in Patients with Peripheral T

• accompanypepsi
• 13 Slides

-Cell . Lymphoma: Final Results of the Phase . Ib....

Behandeling van het recidief ovariumcarcinoom

• sandsomber
• 18 Slides

Ignace Vergote MD PhD FACS FSPS. Chairman, Leuven ...

ASCO 2012 Review Gynecologic Cancer

• welnews
• 66 Slides

Nelson Teng, M.D., Ph.D.. Director, Gynecologic On...

Please note, these are the actual video-recorded

• chaptoe
• 71 Slides

proceedings from the live CME event and may includ...

Please note, these are the actual video-recorded

• blindnessinfluenced
• 27 Slides

proceedings from the live CME event and may includ...

Please note, these are the

• markes
• 20 Slides

actual. . video-recorded proceedings from the . l...

End-Points and Rationale for Phase III Trials in HCC: Adjuvant, Intermediate, and Advanced HCC

• maniakti
• 43 Slides

Richard S. Finn, MD. Professor of Clinical Medicin...

• billiontins
• 108 Slides

2018;36(8):773-9.. Nivolumab Monotherapy (Cohort 1...

Colorectal Cancer in Older

• stingraycartier
• 58 Slides

Patients. Key Issues. Etienne GC . Brain. , MD . P...

MRD = Minimal Resistant Disease?

• shoffer
• 23 Slides

Roger Owen. St James’s Institute of Oncology. Le...

Molecular Lessons Learnt from Clinical Trials in the Last Decade

• altigan
• 62 Slides

Andrew X. Zhu, MD, PhD. Harvard Medical School. Ma...

Ovarian Cancer: Standards of Care and New Opportunities

• majerepr
• 63 Slides

Robert L. Coleman, M.D.. Professor & . Vice Ch...

Sizing the

• callie
• 1 Slides

TAFO : 1. Fit it. Measure for an accurate size . ...

x0000x0000 xMCIxD 0 xMCIxD 0 xMCIxD 1 x

• wang
• 8 Slides

�� &#x/MCI; 1 ;&#x/MCI; 1 ;...

Alumbrera

• tremblay
• 17 Slides

669790 MARA Project Agua Rica – Asset Overvie...

Advances in Systemic Amyloidosis:

• morton
• 62 Slides

A Spotlight on New Disease-Modifying . Therapies A...

Updates on T-cell lymphoma

• grace3
• 18 Slides

Dr. Stefan K. Barta. University of Pennsylvania, U...

Efficacy of sorafenib in patients with

• caitlin
• 1 Slides

desmoid. -type . fibromatosis. Rodrigo Munhoz. 1. ...

iJOURNAL CLUB: Optimizing Therapy for Patients with Metastatic Squamous Cell Carcinoma of the Lung

• berey
• 45 Slides

Interview with Shirish M . Gadgeel. , MD . January...

The Impending D eath of Cancer:

• elina
• 33 Slides

A Herculean Task. Emerging Therapies 2016. Ruemu E...

First Prospective Data on Minimal Residual Disease (MRD) Outcomes After Fixed-Duration Ibrutinib P

• mia
• 23 Slides

Ibr+Ven. ) Versus Chlorambucil Plus Obinutuzumab (...

Impact of Imatinib interruption & duration of prior Hydroxyurea on treatment outcome in CML pat

• hadly
• 17 Slides

Raafat. R. Abdel-. Malek. , MD, FRCR. Ass. Prof C...

The Endocrinology of Neuro ENDOCRINE Tumors

• esther
• 24 Slides

Thomas M. O’Dorisio, MD. HEALING NETs BOOT CAMP....

Paolo Ghia, 1 Andrzej Pluta,

• HappyHippo
• 9 Slides

2. Malgorzata Wach,. 3. Daniel Lysak,. 4. Tomas...

1 A.D. Rollett, Carnegie Mellon Univ

• PeacefulPanda
• 84 Slides

.. 27-750, Texture, Microstructure & . Anisotr...

R eal-world evidence Value, methodological strengths and weaknesses

• Ruggedman
• 21 Slides

What is RWE?. RWE, real-world evidence. .. 1. Food...

Meningioma

• ash
• 36 Slides

SRS post Subtotal Resection Aaron Bush, MD Faculty...

developedtotargetthisfamilyantibodybasedagentsandVEGFreceptorVEGFR

• tremblay
• 15 Slides

Fig.1FlowchartofsearchprocessYuetal.JournalofHemat...

Finra PFS Personal Financial Specialist

• Nicky
• 100 Slides

Prepare Finra PFS Personal Financial Specialist Pr...